Thyroid Cancer in Childhood

  • Nicholas J. Sarlis
  • Wellington Hung
Chapter

Keywords

Thyroid Cancer Thyroid Carcinoma Papillary Thyroid Carcinoma Thyroid Nodule Medullary Thyroid Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Miller RW, Young JL Jr, Novakovic B. Childhood cancer. Cancer 1995; 75:395–405.PubMedGoogle Scholar
  2. 2.
    Harach HR, Williams ED. Childhood thyroid cancer in England and Wales. Br J Cancer 1995; 72:177–783.Google Scholar
  3. 3.
    Belfiore A, LaRosa GL, Padove G, et al. The frequency of cold thyroid nodules and thyroid malignancies in patients from an iodine deficient area. Cancer 1987; 60:3096–3102.PubMedGoogle Scholar
  4. 4.
    Aghini-Lombardi A, Antonangeli L, Martino E, et al. The spectrum of thyroid disorders in an iodinedeficient community: the Pescopagano survey. J Clin Endocrinol Metab 1999; 84:561–566.PubMedGoogle Scholar
  5. 5.
    Quimby EH, Werner SC. Late radiation effects in roentgen therapy for hyperthyroidism. JAMA 1949; 140:1046–1047.Google Scholar
  6. 6.
    Yoshida A, Noguchi S, Fukuda K, et al. Low-dose irradiation to head, neck, or chest during infancy as a possible cause of thyroid carcinoma in teenagers: a match case-control study. Jpn J Cancer 1987; 78:991–994.Google Scholar
  7. 7.
    Prentice RL, Kato H, Mason M, et al. Radiation exposure and thyroid cancer incidence among Hiroshima and Nagasaki residents. National Cancer Institute Monograph 62, 1982: 207–212.PubMedGoogle Scholar
  8. 8.
    US Nuclear Regulatory Commission. Report on the accident at the Chernobyl power station. NUREG-1250. Washington, DC: US Government Printing Office, 1987.Google Scholar
  9. 9.
    Robbins J. Lessons from Chernobyl: the event, the aftermath fallout: radioactive, political, social. Thyroid 1997; 7:182–192.Google Scholar
  10. 10.
    Antonelli A, Miccoli P, Derzhitski VE, et al. Epidemiological and clinical evaluation of thyroid cancer in children corning from the Gomel region (Belarus). World J Surg 1996; 20:867–871.PubMedGoogle Scholar
  11. 11.
    Baverstock K, Egloff B, Pinchera A, et al. Thyroid cancer after Chernobyl. Nature 1992; 359:21–22.PubMedGoogle Scholar
  12. 12.
    Leehardt L, Aurengo A. Post-Chernobyl thyroid carcinoma in children. Baillière’s Clin Endocrinol Metab 2000; 14:667–677.Google Scholar
  13. 13.
    Bounacer A, Wicker R, Caillou B, et al. High prevalence of activating ret proto-oncogene rearrangements in thyroid tumors from patients who had received external radiation. Oncogene 1997; 15:1263–1273.PubMedGoogle Scholar
  14. 14.
    Tuttle RM, Becker DV. The Chernobyl accident and its consequences: update at the millennium. Semin Nucl Med 2000; 30:133–140.PubMedGoogle Scholar
  15. 15.
    Mulligan LM, Kwok JBJ, Healy CS, et al. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363:458–460.PubMedGoogle Scholar
  16. 16.
    Nikiforov YE, Koshoffer A, Nikiforova M, et al. Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegitimate recombination between the ELE1 and RET genes in radiation-induced thyroid carcinomas. Oncogene 1999; 18:6330–6334.PubMedGoogle Scholar
  17. 17.
    Ichihara M, Murakumo Y, Takahashi M. RET and neuroendocrine tumors. Cancer Lett 2004; 204:197–211.PubMedGoogle Scholar
  18. 18.
    Fugazzola L, Pilotti S, Pinchera A, et al. Oncogenic rearrangements of the RET proro-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res 1995; 55:5617–5620.PubMedGoogle Scholar
  19. 19.
    Santoro M, Carlomagno F, Hay ID, et al. RET oncogene activation in human thyroid neoplasms restricted to the papillary subtype. J Clin Invest 1992; 89:1517–1522.PubMedGoogle Scholar
  20. 20.
    Bongarzone I, Fugazzola L, Vigneri P, et al. Age-related activation of the tyrosine kinase receptor protooncogene RET and NTRKl in papillary thyroid carcinoma. J Clin Endocrinol Metab 1996; 81:2006–2009.PubMedGoogle Scholar
  21. 21.
    Rabes HM, Demidchik EP, Sidorow JD, et al. Pattern of radiation-induced RET and NTRKl rearrangements in 191 post-Chernobyl papillary thyroid carcinomas: biological, phenotype, and clinical implications. Clin Cancer Res 2000; 6:1093–1103.PubMedGoogle Scholar
  22. 22.
    Nikiforov YE, Rowland JM, Bove KE, et al. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 1997; 57:1690–1694.PubMedGoogle Scholar
  23. 23.
    Smida J, Salassidis K, Hieber L, et al. Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus. Int J Cancer 1999; 80:32–38.PubMedGoogle Scholar
  24. 24.
    Beimfohr C, Kl.ugbauer S, Demidchik EP, et al. NTRKl re-arrangement in papillary thyroid carcinoma of children after the Chernobyl reactor accident. Int J Cancer 1999; 80:842–847.PubMedGoogle Scholar
  25. 25.
    Santoro M, Thoas G, Williams GH, et al. Gene rearrangement and Chernobyl related thyroid cancers. Br J Cancer 2000; 82:315–322.PubMedGoogle Scholar
  26. 26.
    Namba H, Rubin SA, Fagin JA. Point mutations are an early event in thyroid tumorigenesis. Mol Endocrinol 1990; 4:1474–1479.PubMedGoogle Scholar
  27. 27.
    Lemoine NR, Mayall ES, Wyllier FS, et al. High frequency of RAS oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989; 4:159–164.PubMedGoogle Scholar
  28. 28.
    Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgamma-1 fusion oncogene in human thyroid carcinoma. Science 2000; 289:1357–1360.PubMedGoogle Scholar
  29. 29.
    Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003; 88:2318–2326.PubMedGoogle Scholar
  30. 30.
    Saez E, Rosenfeld J, Livolsi A, et al. PPAR-gamma signaling exacerbates mammary gland tumor development. Genes Dev 2004; 18:528–540.PubMedGoogle Scholar
  31. 31.
    Grigsby PW, Gal-or A, Michalski JM, et al. Childhood and adolescent thyroid carcinoma. Cancer 2002; 95:724–729.PubMedGoogle Scholar
  32. 32.
    Sarlis NJ. Expression patterns of cellular growth-controlling genes in non-medullary thyroid cancer: basic aspects. Rev Endocr Metab Disord 2000; 1:183–196.PubMedGoogle Scholar
  33. 33.
    Blatt J, Gishan A, Gula MJ, et al. Second malignancies in very long term survivors of cancer. Am J Med 1992; 93:57–60.PubMedGoogle Scholar
  34. 34.
    Gow KW, Lensing S, Hill DA, et al. Thyroid carcinoma presenting in childhood or after treatment of childhood malignancies: an institutional experience and review of the literature. J Pediatr Surg 2003; 38:1574–1580.PubMedGoogle Scholar
  35. 35.
    De Keyser LFM, Van Herle AJ. Thyroid cancer in children. Head Neck Surg 1985; 8:100–114.PubMedGoogle Scholar
  36. 36.
    Pal T, Vogl FD, Chappuis PO, et al. Increased risk for nonmedullary thyroid cancers in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab 2001; 86:5307–5312.PubMedGoogle Scholar
  37. 37.
    Steiner AL, Goodman AD, Powers SR. Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing’s disease: multiple endocrine neoplasia, type 2. Medicine (Baltimore) 1968; 47:371–409.PubMedGoogle Scholar
  38. 38.
    Schimke RN, Hartmann WH, Prout TE, et al. Syndrome of bilateral pheochromocytomas, medullary thyroid carcinoma and multiple neuromas: a possible regulatory defect in differentiation of chromaffin tissue. N Engl J Med 1968; 279:1–7.PubMedGoogle Scholar
  39. 39.
    Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN Type 1 and Type 2. J Clin Endocrinol Metab 2001; 86:5658–5671.PubMedGoogle Scholar
  40. 40.
    Farndon JR, Leight GS, Dilley WG, et al. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg 1986; 73:278–281.PubMedGoogle Scholar
  41. 41.
    Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene associated with MEN 2A and FMTC. Hum Mol Genet 1993; 2:851–856.PubMedGoogle Scholar
  42. 42.
    Komminoth P, Roth J, Muletta-Feurer S, et al. RET proto-oncogene point mutations in sporadic neuroendocrine tumors. J Clin Endocrinol Metab 1996; 81:2041–2046.PubMedGoogle Scholar
  43. 43.
    Bucsky P, Parlowsky T. Epidemiology and therapy of thyroid cancer in childhood and adolescence. Exp Clin Endocrinol Diabetes 1997; 105(Suppl 4):70–73.PubMedGoogle Scholar
  44. 44.
    Ain KB. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 1998; 8:716–726.Google Scholar
  45. 45.
    Fagin JA, Matsuo K, Karmakar A, et al. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993; 91:179–184.PubMedGoogle Scholar
  46. 46.
    Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985–1995. Cancer 1998; 83:2638–2648.PubMedGoogle Scholar
  47. 47.
    Wenig BM, Heffess CS, Adair CF. Atlas of endocrine pathology. Philadelphia: WB Saunders, 1997.Google Scholar
  48. 48.
    Sherman SI. Thyroid carcinoma. Lancet 2003; 361:501–511.PubMedGoogle Scholar
  49. 49.
    Garcia CJ, Daneman A, Thorner P, et al. Sonography of multinodular thyroid gland in children and adolescents. Am J Dis Child 1992; 146:811–816.PubMedGoogle Scholar
  50. 50.
    Telander RL, Zimmerman D, Sizemore GW, et al. Medullary carcinoma in children: results of early detection and surgery. Arch Surg 1989; 124:841–843.PubMedGoogle Scholar
  51. 51.
    Ledger GA, Khosla S, Lindor NM, et al. Genetic testing in the diagnosis and management of multiple endocrine neoplasia type II. Ann Intern Med 1995; 122:118–124.PubMedGoogle Scholar
  52. 52.
    Wells SA Jr, Donis-Keller H. Current perspectives on the diagnosis and management of patients with multiple endocrine neoplasia type 2 syndromes. Endocrinol Metab Clin North Am 1994; 23:215–228.PubMedGoogle Scholar
  53. 53.
    Marsh DJ, Robinson BG, Andrew S, et al. A rapid screening method for the detection of mutations in the RET proto-oncogene in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma families. Genomics 1994; 23:477–479.PubMedGoogle Scholar
  54. 54.
    Heptulla RA, Schwartz RP, Bale AE, et al. Familial medullary thyroid carcinoma: presymptomatic diagnosis and management in children. J Pediatr 1999; 135:327–331.PubMedGoogle Scholar
  55. 55.
    Lips CJM, Landsvater RM, Hoppener JWM, et al. 1994 Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994; 331:828–835.PubMedGoogle Scholar
  56. 56.
    Croom RD IIIrd, Thomas CG Jr, Reddick RL. Autonomously functioning thyroid nodules in childhood and adolescence. Surgery 1987; 102:1101–1108.PubMedGoogle Scholar
  57. 57.
    Hung W. Solitary thyroid nodules in 93 children and adolescents: a 35-years experience. Horm Res 1999; 52:15–18.PubMedGoogle Scholar
  58. 58.
    Desjardin JG, Khan AH, Montupet P, et al. Management of thyroid nodules in children: a 20-year experience. J Pediatr 1987; 22:736–739.Google Scholar
  59. 59.
    Lugo-Vicente H, Ortiz VN, Irizarry H, et al. Pediatric thyroid nodules: management in the era of fine needle aspiration. J Pediatr Surg 1998; 33:1302–1305.PubMedGoogle Scholar
  60. 60.
    Gharib H, Mazzaferri EL. Thyroxine suppressive therapy in patients with nodular thyroid disease. Ann Intern Med 1998; 128:386–394.PubMedGoogle Scholar
  61. 61.
    Csako G, Byrd D, Wesley RA, et al. Assessing the effects of thyroid suppression on benign solitary thyroid nodules. A model for using quantitative research synthesis. Medicine (Baltimore) 2000; 79:9–26.PubMedGoogle Scholar
  62. 62.
    Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association. Arch Intern Med 1996; 156:2165–2172.PubMedGoogle Scholar
  63. 63.
    Corrias A, E1naudi S, Chiorboli E, et al. Accuracy of fine-needle aspiration biopsy of thyroid nodules in detecting malignancy in childhood: comparison with conventional clinical, laboratory and imaging approaches. J Clin Endocrinol Metab 2001; 86:4644–4648.PubMedGoogle Scholar
  64. 64.
    Al-Shaikh A, Ngan B, Daneman A, et al. Fine-needle aspiration biopsy in the management of thyroid nodules in children and adolescents. J Pediatr 2001; 138:140–142.PubMedGoogle Scholar
  65. 65.
    Gorlin JB, Sallen SE. Cancer in childhood. Endocrinol Metab Clin North Am 1990; 19:649–662.PubMedGoogle Scholar
  66. 66.
    Hung W, Sarlis NJ. Current controversies in the management of pediatric patients with well-differentiated nonmedullary thyroid cancer: A review. Thyroid 2002; 12:683–702.PubMedGoogle Scholar
  67. 67.
    Friedman M, Pacella BC Jr. Total versus subtotal thyroidectomy: arguments, approaches, and recommendations. Otolaryngol Clin North Am 1990; 23:413–427.PubMedGoogle Scholar
  68. 68.
    De Jong SA, Demeter JG, Lawrence AM, et al. Necessity and safety of completion thyroidectomy for differentiated thyroid carcinoma. Surgery 1992; 112:734–739.PubMedGoogle Scholar
  69. 69.
    Robie DK, Dinauer CW, Tuttle RM, et al. The impact of initial surgical management on outcome in young patients with differentiated thyroid cancer. J Pediatr Surg 1998; 33:1134–1140.PubMedGoogle Scholar
  70. 71.
    Dottorini ME, Vignati A, Mazzucchelli L, et al. Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients. J Nucl Med 1997; 38:669–675.PubMedGoogle Scholar
  71. 72.
    Hallwirth U, Flores J, Kaserer K, et al. Differentiated thyroid cancer in children and adolescents: the importance of adequate surgery and review of the literature. Eur J Pediatr Surg 1999; 9:359–363.PubMedGoogle Scholar
  72. 72.
    Katoh R, Sasaki J, Kurihara H, et al. Multiple thyroid involvement in intraglandular metastases in papillary thyroid carcinoma. Cancer 1992; 70:1585–1590.PubMedGoogle Scholar
  73. 73.
    Paryani SB, Chobe RJ, Scott W, et al. Management of thyroid carcinoma with radioactive 131I. Int J Radiat Oncol Biol Phys 1996; 36(Suppl):S83–S86.Google Scholar
  74. 74.
    Yeh SD, La Quaglia MP. 131-I therapy for pediatric cancer. Semin Pediatr Surg 1997; 6:128–133.PubMedGoogle Scholar
  75. 75.
    Sherman SI, Tielens ET, Sostre S, et al. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 1994; 78:629–634.PubMedGoogle Scholar
  76. 76.
    Mazzaferri EL, Kloos RT. Using recombinant human TSH in the management of thyroid cancer: current strategies and future direction. Thyroid 2000; 10:767–778.PubMedGoogle Scholar
  77. 77.
    Mandel SJ, Shankar LK, Benard F, et al. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. J Nucl Med 2001; 26:6–9.Google Scholar
  78. 78.
    Park HM, Perkins OW, Edmondson JW, et al. Influence of diagnostic radioiodine in the uptake of ablative dose iodine-131. Thyroid 1994; 4:49–54.PubMedGoogle Scholar
  79. 79.
    Reynolds JC. Comparison of I-131 absorbed radiation doses in children and adults: a tool for estimating therapeutic I-131 doses in children. In: Robbins J (ed.) Treatment of thyroid cancer in childhood. Washington, DC: Department of Energy (Publication DOE/EH-0406), 1993:127–135.Google Scholar
  80. 80.
    Beierwaltes WH. Radioiodine therapy of thyroid disease. Int J Rad Appl Instrum B 1987; 14:177–181.PubMedGoogle Scholar
  81. 81.
    Maxon HR IIIrd Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. Q J Nucl Med 1999; 43:313–323.PubMedGoogle Scholar
  82. 82.
    Wiersinga WM. Thyroid cancer in children and adolescents — consequences in later life. J Pediatr Endocrinol Metab 2001; 14:1289–1296.PubMedGoogle Scholar
  83. 83.
    Menzel C, Grunwald P, Schomburg A. “High-dose” radioiodine therapy in advanced differentiated thyroid carcinoma. J Nucl Med 1996; 37:1496–1503.PubMedGoogle Scholar
  84. 84.
    Sisson JC. Medical treatment of benign and malignant thyroid tumors. Endocrinol Metab Clin North Am 1989; 18:359–387.PubMedGoogle Scholar
  85. 85.
    Schlumberger M, De Vathaire P, Ceccarelli C. Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med 1996; 37:606–611.PubMedGoogle Scholar
  86. 86.
    Mazzaferri EL, Young RL, Oertel JE. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine (Baltimore) 1977; 56:171–196.PubMedGoogle Scholar
  87. 87.
    Vassilopoulou-Sellin R, Goepfert H, Raney B, et al. Differentiated thyroid cancer in children and adolescents: clinical outcome and mortality after long-term follow-up. Head Neck 1998; 20:549–555.PubMedGoogle Scholar
  88. 88.
    Burmeister L, Goumaz MO, Mariash CN, et al. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 1992; 75:344–350.PubMedGoogle Scholar
  89. 89.
    McGriff NJ, Csako G, Gourgiotis L, et al. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 2002; 34:554–564.PubMedGoogle Scholar
  90. 90.
    Brierley JD, Tsang RW. External-beam radiation therapy in the treatment of differentiated thyroid cancer. Semin Surg Oncol 1999; 16:42–49.PubMedGoogle Scholar
  91. 91.
    Bonadonna G, Beretta G, Tancini G, et al. Adriamycin as a single agent in various forms of advanced neoplasia of adults and children. Tumori 1974; 60:373–391 [in Italian].PubMedGoogle Scholar
  92. 92.
    Patel A, Pluim T, Helms A, et al. Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults. Cancer Chemother Pharmacol 2004; 53:409–414.PubMedGoogle Scholar
  93. 93.
    Kirk JMW, Mort C, Grant DB, et al. The usefulness of serum thyroglobulin in the follow-up of differentiated thyroid carcinoma in children. Med Pediatr Oncol 1992; 20:201–208.PubMedGoogle Scholar
  94. 94.
    Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88:1433–1441.PubMedGoogle Scholar
  95. 95.
    Spencer CA. Serum thyroglobulin measurements: clinical utility and technical limitations in the management of patients with differentiated thyroid carcinoma. Endocr Pract 2000; 6:481–484.PubMedGoogle Scholar
  96. 96.
    Robbins J. Management of thyroglobulin-positive, body-scan negative thyroid cancer patients: evidence for the utility of I-131 therapy. J Endocrinol Invest 1999; 22:808–810.PubMedGoogle Scholar
  97. 97.
    Samuel AM, Rajashejharrao B, Shah DH. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. J Nucl Med 1998; 39:1531–1536.PubMedGoogle Scholar
  98. 98.
    Vassilopoulou-Sellin R, Libshitz HI, Haynie TP. Papillary thyroid cancer with pulmonary metastases beginning in childhood: clinical course over three decades. Med Pediatr Oncol 1995; 24:119–122.PubMedGoogle Scholar
  99. 99.
    Telander RL, Moir CR. Medullary thyroid carcinoma in children. Semin Pediatr Surg 1994; 3:188–193.PubMedGoogle Scholar
  100. 100.
    Skinner MA, DeBenedetti JF, Norton JA, et al. Medullary thyroid endocrine neoplasia type 2A and 2B. J Pediatr Surg 1996; 31:177–181.PubMedGoogle Scholar
  101. 101.
    Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003; 349:1517–1525.PubMedGoogle Scholar
  102. 102.
    Cote GJ, Gagel RF. Lessons learned from the management of a rare genetic cancer. N Engl J Med 2003; 349:1566–1568.PubMedGoogle Scholar
  103. 103.
    Brierley J, Tsang R, Simpson WJ, et al. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996; 6:305–310.PubMedGoogle Scholar
  104. 104.
    Krausz Y, Rosler A, Guttmann H, et al. Somatostatin receptor scintigraphy for early detection of regional and distant metastases of medullary carcinoma of the thyroid. Clin Nucl Med 1999; 24:256–260.PubMedGoogle Scholar
  105. 105.
    McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001; 130:1028–1034.PubMedGoogle Scholar
  106. 106.
    Winship T, Rosvoll R. Thyroid carcinoma in childhood: final report on a 20 year study. Clin Proc Child Hosp Washington DC 1970; 26:327–349.Google Scholar
  107. 107.
    Zimmerman D, Hay ID, Gough IR, et al. Papillary thyroid carcinoma in children and follow-up of 1039 patients conservatively in one institution during three decades. Surgery 1988; 104:1157–1166.PubMedGoogle Scholar
  108. 108.
    La Quaglia MP, Corbally MT, Heller G. Recurrence and morbidity in differentiated thyroid carcinoma in children. Surgery 1988; 104:1149–1156.PubMedGoogle Scholar
  109. 109.
    Powers PA, Dinauer CA, Tuttle RM, et al. Treatment of recurrent papillary thyroid carcinoma in children and adolescents. J Pediatr Endocrinol Metab 2003; 16:1033–1040.PubMedGoogle Scholar
  110. 110.
    Jarzab B, Junak DH, Wloch J, et al. Multivariate analysis of prognostic factors for differentiated thyroid carcinoma in children. Eur J Nucl Med 2000; 27:833–841.PubMedGoogle Scholar
  111. 111.
    Alessandri AJ, Goddard KJ, Blair GK, et al. Age is the major determinant of recurrence in pediatric thyroid carcinoma. Med Pediatr Oncol 2000; 35:41–46.PubMedGoogle Scholar
  112. 112.
    Dottorini ME. Differentiated thyroid carcinoma in childhood. Rays 2000; 25:245–255.PubMedGoogle Scholar
  113. 113.
    Parlowsky T, Bucsky P, Hof M, et al. Malignant endocrine tumours in childhood and adolescence — results of a retrospective analysis. Klin Paediatr 1996; 208:205–209.Google Scholar
  114. 114.
    van Heerden A, Grant CS, Gharib H, et al. Long-term course of patients with persistent hypercalcitoninemia after curative primary surgery. Ann Surg 1990; 212:395–400.PubMedGoogle Scholar
  115. 115.
    Gill JR, Reyes-Mugica M, Lyengar S, et al. Early presentation of metastatic medullary carcinoma in multiple endocrine neoplasia, type IIA: implications for therapy. J Pediatr 1996; 129:459–464.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2006

Authors and Affiliations

  • Nicholas J. Sarlis
    • 1
  • Wellington Hung
    • 2
  1. 1.Department of Endocrine Neoplasia and Hormonal DisordersThe University of Texas M. D. Anderson Cancer CenterHoustonUSA
  2. 2.Developmental Endocrinology Branch, National Institute of Child Health and Human, DevelopmentNational Institutes of HealthBethesdaUSA

Personalised recommendations